FS 102

Drug Profile

FS 102

Alternative Names: BMS-986186; FS102

Latest Information Update: 25 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator f-star
  • Developer Bristol-Myers Squibb
  • Class Antineoplastics; Bispecific antibodies; Drug conjugates; Immunoglobulin Fc fragments; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; ERBB 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Breast cancer; Gastric cancer; Solid tumours

Most Recent Events

  • 08 Jun 2017 Bristol-Myers Squibb completes a phase I trial in Solid tumours, including Breast cancer and Gastric cancer in USA and Canada (NCT02286219)
  • 05 Oct 2015 Pharmacodynamics data from preclinical trials in Breast cancer released by F-star
  • 09 Jan 2015 Phase-I clinical trials in Breast cancer (Late-stage disease, Second-line therapy or greater) in USA (IV) (9173463; NCT02286219)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top